Company Overview and News

 
Shriram Transport Finance recoups losses to rally 4% after management clarification on SVL case

2018-09-14 moneycontrol
Shriram Transport Finance Corporation share price fell nearly 4 percent in early trade but managed to recoup those losses to rally more than 4 percent intraday on Friday, after the management clarified on SVL case.
511218 532498 SHRIRAMCIT SRRQY SRTRANSFIN

 
Broker's Call: Shriram Transport (Buy)

2018-09-03 thehindubusinessline
Shriram Transport Finance has shown recovery in assests under management (AUM) since the last few quarters backed by strong CV demand in the country. Infrastructure development and recovery in rural economy has kept AUM growth stronger. IND-AS (Indian accounting standards) transition has been positive.
511218 SRRQY SRTRANSFIN

 
Fund raising via NCDs jumps to Rs 21,048 cr in April-July

2018-09-03 thehindubusinessline
As many as seven companies raised over Rs 21,000 crore through issuance of debentures during April-July period of the ongoing fiscal, a surge of nearly five times from the year-ago period.
511218 DHFL MUTHOOTFIN 511072 SRRQY 533398 SRTRANSFIN

 
Fund raising via NCDs rises 5 times to Rs 21,000 crore in Apr-Jul

2018-09-03 moneycontrol
As many as seven companies raised over Rs 21,000 crore through issuance of debentures during April-July period of the ongoing fiscal, a surge of nearly five times from the year-ago period.
511218 DHFL MUTHOOTFIN 511072 SRRQY 533398 SRTRANSFIN

 
Uday Kotak, Asia’s richest banker, may acquire rivals after RBI’s rebuff

2018-08-28 livemint
Mumbai: A rebuff from the regulator may set Asia’s richest banker Uday Kotak on a $17 billion acquisition trail, as he seeks to meet a year-end deadline to reduce his stake in Kotak Mahindra Bank Ltd. below 20 percent. Buying another financial firm may be the most palatable way for Kotak to pare his holding, following the Reserve Bank of India’s rejection earlier this month of a preference share sale proposal.
511218 AXBKY AXBA AXB KMBKY AXISBANK SRRQY KOTAKBANK 500247 SRTRANSFIN 532215

 
Asia's richest banker may acquire rivals after RBI's rebuff

2018-08-28 malaymail
MUMBAI, Aug 28 — A rebuff from the regulator may set Asia’s richest banker Uday Kotak on a US$17 billion (RM69.5 billion) acquisition trail, as he seeks to meet a year-end deadline to reduce his stake in Kotak Mahindra Bank Ltd below 20 per cent.
511218 AXBKY AXBA AXB KMBKY AXISBANK SRRQY KOTAKBANK 500247 SRTRANSFIN 532215

 
Asia's richest banker may acquire rivals after RBI's rebuff

2018-08-28 theedgemarkets
MUMBAI (Aug 28): A rebuff from the regulator may set Asia’s richest banker Uday Kotak on a US$17 billion acquisition trail, as he seeks to meet a year-end deadline to reduce his stake in Kotak Mahindra Bank Ltd below 20%.
511218 AXBKY AXBA AXB KMBKY AXISBANK SRRQY KOTAKBANK 500247 SRTRANSFIN 532215

 
An evening walk down Dalal Street | Global cues, banks and metals fuel rally on D-Street; Nifty ends just below 11,700

2018-08-27 moneycontrol
What a cracker of a Monday that was for the market! Bulls had it their way throughout the session, gaining with every passing hour. Benchmarks ended the day at record high levels. The Nifty managed to clock 11,700-mark as well.
500325 SUNDARMFIN 570002 RELIANCE FRL 532978 BHRQY SRTRANSFIN 511218 532454 BAJAJFINSV LICHSGFIN FRLDVR RIGD SRRQY 523574 LHFLY BHARTIARTL 590071 500253 RLNIY SNDMY

 
Shriram Transport up 4%; foreign brokerages maintain buy with target upto Rs 1,890

2018-08-27 moneycontrol
Shares of Shriram Transport Finance Corporation added 4.6 percent intraday Monday as foreign research house maintained buy on the stock with a target upto Rs 1,890 per share.
511218 SRRQY SRTRANSFIN

 
TPG leads $100 million funding in non-bank lender Five Star Business Finance

2018-07-31 livemint
Mumbai: Global alternative asset firm TPG said on Tuesday it has led a $100 million (Rs685 crore) investment round in non-bank lender Five Star Business Finance Ltd. The round also saw participation from existing investors Norwest Venture Partners, an investment fund managed by Morgan Stanley, and Sequoia Capital. Five Star’s first institutional investor, Matrix Partners, continues to stay invested in the company, TPG said.
UBNC SRTRANSFIN 511218 532498 SHRIRAMCIT SRRQY MS

4
India Inc#39;s external borrowing jumps 66% to $2.71 bn in Jun

2018-07-30 moneycontrol
India Inc raised USD 2.71 billion through external commercial borrowing (ECB) and rupee-denominated bonds (RDBs) in June 2018, up by 66.3 per cent over the same month last year, the RBI data released today showed. Indian companies had raised USD 1.63 billion from overseas sources in June 2017.
511218 535789 IBULHSGFIN SRRQY IDKQY 500570 SRTRANSFIN TATAMOTORS TTM

 
India Inc garners Rs 19,000 cr via NCDs in April-July

2018-07-30 thehindubusinessline
As many as six companies raised over Rs 19,000 crore through issuance of debentures during April-July period of the ongoing fiscal, a surge of five times from the year-ago period.
511218 DHFL ICICIBANK MUTHOOTFIN 511072 532174 IBN SRRQY 533398 SRTRANSFIN SBAZ

 
Broker's call: Shriram Transport Finance

2018-07-09 thehindubusinessline
In our May 2018 reinitiating coverage note on Shriram Transport Finance (SHTF), we had indicated that 1) we expect per cent16 per cent 3-year AUM CAGR of SHTF as the estimated financing opportunity for 5-10 year pre-owned vehicles is ₹2.5 lakh crore, ii) With NPA recognition at 90+ DPD, pace of fresh NPA creation will moderate leading to improvement in FY19E credit cost; and 3) margins can come under pressure if SHTF targets lower vintage vehicles.
511218 500470 TTST TATASTEEL TATLY SRRQY SRTRANSFIN

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...